NCT06702566View on ClinicalTrials.gov

The Effect of Serum Ferritin in irAE

NARecruitingINTERVENTIONAL
Enrollment

1,500

Participants

Timeline

Start Date

July 4, 2024

Primary Completion Date

July 16, 2026

Study Completion Date

July 1, 2027

Conditions
Immune-related Adverse EventMalignant Solid TumorsAcute LeukemiaSerum Ferritin
Interventions
DRUG

PD-1 and PD-L1 inhibitor

"PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.~PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab."

DRUG

Targeted drugs

Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs

DRUG

chemotherapy drugs

Chemotherapy drugs are determined based on the investigator's decision.

Trial Locations (1)

300060

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER